Henshaw Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Henshaw Capital’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,512	Closed	-$209K	–	265
2022 Q4	$209K	Buy	+4,512	New	+$177K	0.01%	229
2022 Q3	–	Sell	-4,512	Closed	-$269K	–	313
2022 Q2	$269K	Buy	4,512 +628	+16%	+$38.6K	0.02%	242
2022 Q1	$282K	Hold	3,884	–	–	0.02%	260
2021 Q4	$327K	Hold	3,884	–	–	0.02%	241
2021 Q3	$350K	Hold	3,884	–	–	0.02%	220
2021 Q2	$370K	Sell	3,884 -370	-9%	-$38.5K	0.02%	228
2021 Q1	$484K	Sell	4,254 -366	-8%	-$49.8K	0.03%	171
2020 Q4	$640K	Sell	4,620 -1,101	-19%	-$131K	0.05%	134
2020 Q3	$470K	Sell	5,721 -794	-12%	-$65.8K	0.04%	162
2020 Q2	$510K	Hold	6,515	–	–	0.04%	143
2020 Q1	$289K	Buy	+6,515	New	+$338K	0.03%	196

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Henshaw Capital's RARE Position: Q1 2023 in Review

Henshaw Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2023, closing a stake of 4,512 shares — an estimated $209K sold.

Henshaw Capital first reported a position in RARE in Q1 2020 and held it in 11 quarters. The position peaked at $640K in Q4 2020. 229 funds tracked by Wall St. Rank hold RARE as of Q1 2023.

Henshaw Capital reported no remaining Ultragenyx Pharmaceutical position as of Q1 2023 after selling out during the quarter.
Henshaw Capital sold 4,512 Ultragenyx Pharmaceutical shares in Q1 2023, an estimated $209K.
Henshaw Capital first reported a position in Ultragenyx Pharmaceutical in Q1 2020 and held it in 11 quarters.
Henshaw Capital's Ultragenyx Pharmaceutical position peaked at $640K in Q4 2020.
229 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2023.

Based on Henshaw Capital's 13F filing for Q1 2023, filed 28 May 2026.